Monitoring immune response is critical in drug development. Accurate cytokine quantification impacts efficacy evaluation, safety assessments, and regulatory approvals. Cytokine assays are essential tools for quantifying immune response biomarkers and inflammatory mediators that govern safety profiles and therapeutic outcomes. Cytokine quantification is crucial for characterizing drug mechanisms, assessing immunotoxicity, and monitoring treatment responses throughout development programs.
Today, specialized clinical bioanalysis solutions offer analytical support vital for successful preclinical research and project execution. This article discusses cytokine analysis, clinical applications, and methodologies supporting drug discovery and development.
Cytokine analysis: Ideal approach to disease management and drug development
Cytokines are a class of soluble proteins, peptides, and glycoproteins that function as chemical messengers of the immune responses. These proteins are vital intercellular communicators that carry messages among cells and contribute to immune responses and cellular growth. Cytokines include interferons, chemokines, lymphokines, and interleukins. These molecules cannot cross the lipid bilayer. Cytokines are key elements in paracrine, autocrine, and endocrine signaling.
As cytokines are involved in crucial regulatory functions, researchers are focused heavily on understanding cytokine messaging, how data travels, and the role they play in immunology and disease mechanisms. Data suggest cytokines may have promising applications in the diagnosis and treatment of diseases such as autoimmune diseases, cancer, and septic shock. However, scientists need reliable methods to determine and measure cytokines in complex biological matrices.
Cytokines and their clinical utility
Cytokine Assays have their unique challenges. However, low costs and a lack of invasiveness make them an ideal approach for clinicians and researchers. Chronic inflammation is a contributing factor to several ailments and diseases. Hence, it is one such avenue where cytokine analysis is quite helpful. The NIH states that one of the most crucial medical findings of the past 20 years is the discovery that inflammatory processes and the immune system are not only involved in a few disorders but play a critical role in health problems faced by the current population. Through biochemical interactions, cytokines, including chemokines, interleukins, and interferons, all have an inherent property of exhibiting anti-inflammatory and pro-inflammatory effects throughout the body. Recently, cytokines have been studied to identify patterns in specific disorders and diseases.
However, using cytokine data to study diseases and disorders was not so common until recently. In August 2020, scientists from Mount Sinai Health System discovered cytokine protein markers that predicted and determined COVID-19 severity in patients and their survival rates. Their press release stated that the scientist studied four cytokines commonly associated with infections. They discovered that two of those, TNF-α and IL-6, predicted which patients had a higher chance of getting severe Covid-19 and dying. They further stated that this investigation suggests that these two cytokines should be studied and monitored for treating COVID-19 patients.
The major challenge with cytokine analysis is its ability to distinguish between abnormal and normal cytokine levels. Variables differ among patients and can potentially modify how cytokines are activated and spread through the system. These variables include physiological factors, increased stress levels, dietary habits, and physical fitness.
As the accuracy and reliability of cytokine quantification increase, the understanding of these processes will also increase over time. This advancement will allow scientists to detect abnormalities earlier. With enhanced cytokine assay sensitivity becoming readily available for researchers and clinicians, they are finally exploring approaches to prevent diseases and discover novel therapeutics.
Must Read: How to Choose the Right Biochemical Assay for Your Experiment?
Cytokine testing platforms
Immunoassay platforms are currently the popular choice for cytokine quantification. Let us explore different platforms for cytokine analysis.
ELISA assays
ELISA is one of the most common methods employed for cytokine analysis. This method uses a primary capture antibody and a secondary conjugated antibody for detection. Although singleplex ELISA kits are available for cytokine quantification, newer multiplex assays are overcoming the limitations faced by singleplex assays.
ELISpot
The cytokine ELISpot is both a qualitative and quantitative assay. Today, it has emerged as a crucial tool for clinicians and researchers to monitor human immune responses. This method can detect and monitor immune responses against specific antigens and evaluate cytokine release from activated innate immune cells. The ELISpot assay is based on the ELISA technique and can effectively measure responses to a broad variety of stimuli.
MSD-ECL
MSD-ECL is similar to ELISA assays, but it uses electrochemiluminescence detection instead of colorimetric readouts. These methods provide higher sensitivity, ultrasensitive detection, and broader dynamic range. Most importantly, it uses lower sample volumes. The MSD platform is ideal for identifying and assessing patterns in cytokine profiles.
Flow cytometry
Flow cytometry is an effective method to determine and measure cytokines in complex matrices. This method can be performed in under two hours. Flow cytometry is generally used to detect intracellular cytokines.
Conclusion
Cytokine analysis is vital in enhancing the success of clinical trials and drug development projects. Validated cytokine assay platforms are necessary for supporting regulatory submissions and clinical decision-making. A comprehensive cytokine quantification capabilities and unique Clinical Bioanalysis Services ensures project success across therapeutic areas. Hence, understanding the strategic potential of cytokine analysis is essential for improving treatment outcomes and advancing therapeutic innovation.
